{"id":"symbicort-pmdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Budesonide suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation and improving airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.","oneSentence":"Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:49.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance treatment"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT07433569","phase":"PHASE1","title":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Asthma","enrollment":12},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT04609904","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-01","conditions":"Asthma","enrollment":2187},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06571942","phase":"PHASE4","title":"Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","status":"RECRUITING","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2023-11-15","conditions":"COPD Bronchitis, Pollution Related Respiratory Disorder","enrollment":128},{"nctId":"NCT05084222","phase":"PHASE4","title":"Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-11-11","conditions":"Asthma","enrollment":180},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT00915538","phase":"PHASE4","title":"Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)","status":"COMPLETED","sponsor":"Western Sky Medical Research","startDate":"2009-07","conditions":"Asthma","enrollment":16},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT02495168","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-01-13","conditions":"Asthma","enrollment":1714},{"nctId":"NCT02864342","phase":"PHASE4","title":"Adherence Study in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD","enrollment":138},{"nctId":"NCT01099722","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2010-04","conditions":"Asthma","enrollment":261},{"nctId":"NCT02934607","phase":"PHASE1","title":"A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-04","conditions":"Study is Being Conducted in Healthy Volunteers","enrollment":50},{"nctId":"NCT02533505","phase":"PHASE4","title":"Phase IV O2 Consumption Study in COPD Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":51},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT02233803","phase":"PHASE4","title":"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-14","conditions":"Asthma","enrollment":239},{"nctId":"NCT02091986","phase":"PHASE3","title":"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04","conditions":"Asthma","enrollment":882},{"nctId":"NCT01444430","phase":"PHASE3","title":"A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12","conditions":"Asthma","enrollment":12460},{"nctId":"NCT01360021","phase":"PHASE3","title":"New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Asthma","enrollment":214},{"nctId":"NCT01136655","phase":"PHASE2","title":"A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Asthma","enrollment":54},{"nctId":"NCT00702325","phase":"PHASE4","title":"Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Asthma","enrollment":311},{"nctId":"NCT00419952","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Asthma","enrollment":742},{"nctId":"NCT00419757","phase":"PHASE3","title":"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Asthma","enrollment":558},{"nctId":"NCT00536731","phase":"PHASE3","title":"Symbicort Rapihaler Therapeutic Equivalence Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Bronchial Asthma","enrollment":742},{"nctId":"NCT00536913","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Asthma","enrollment":107},{"nctId":"NCT00651768","phase":"PHASE3","title":"Titratable Dosing in Moderate to Severe Asthmatics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-08","conditions":"Asthma","enrollment":570},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00646516","phase":"PHASE3","title":"Gemini Symbicort pMDI","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-10","conditions":"Mild or Moderate Asthma","enrollment":615},{"nctId":"NCT00449501","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":134},{"nctId":"NCT00652392","phase":"PHASE3","title":"Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":750},{"nctId":"NCT00646321","phase":"PHASE3","title":"Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":540},{"nctId":"NCT00658255","phase":"PHASE2","title":"Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-10","conditions":"Stable Asthma","enrollment":175},{"nctId":"NCT00449527","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":123},{"nctId":"NCT00419744","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1200},{"nctId":"NCT00646620","phase":"PHASE3","title":"Symbicort Onset of Action 1","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":48},{"nctId":"NCT00206154","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1500},{"nctId":"NCT00421122","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":315},{"nctId":"NCT00206167","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1600},{"nctId":"NCT00646594","phase":"PHASE3","title":"Atlantis Symbicort","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Asthma","enrollment":1200},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Symbicort pMDI","genericName":"Symbicort pMDI","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}